Combination Cardiovascular Therapies Show Promise in Slowing Cognitive Decline and Reducing Dementia Pathology
Key Insights
A large study of 4,651 older adults found that patients using combinations of antihypertensive, lipid-lowering, and antidiabetes medications (search) experienced slower cognitive decline compared to those using no medications.
Autopsy analysis of 1,896 participants revealed that combination therapy users had lower odds of atherosclerosis (search) and arteriolosclerosis (search), along with reduced Alzheimer's disease (search) pathology including amyloid (search) and tangle burden.
The research suggests that early interventions with combination therapies targeting multiple vascular metabolic risk factors could potentially delay or prevent cognitive decline and dementia (search).
Patients who used combinations of cardiovascular therapies experienced slower cognitive decline and fewer neuropathologies related to dementia (search), according to data presented at the Alzheimer's Association International Conference. The findings suggest that targeting multiple vascular metabolic risk factors simultaneously may offer a promising approach to preventing dementia.
The study included 4,651 older adults with an average age of 77 years, 75% women, and 28% Black participants who had no baseline dementia (search) but had two or more global cognition measures collected annually. Documentation of visual inspections of their medications was collected annually as well.
Triple Therapy Shows Strongest Cognitive Protection
Patients who used all three classes of medications — antihypertensive, lipid-lowering and antidiabetes — had slower decline in global cognition compared with those who used no medications (P = .02), particularly in semantic and working memory domains.
"Hypertension (search), dyslipidemia (search), and diabetes (search) are common conditions in older adults and are known dementia (search) risk factors," said Roshni Biswas, MBBS, PhD, MPH, research scientist at Rush Alzheimer's Disease Center (search). "Since older adults are often on combination therapies, we aimed to assess the impact of combination therapies with these three common medication classes on cognitive decline."
Neuropathological Benefits Revealed Through Autopsy Analysis
Autopsies of 1,896 deceased patients included evaluations for dementia (search)-related neuropathologies such as cerebrovascular disease and Alzheimer's disease (search). Among autopsied patients who had used all three classes, odds for atherosclerosis (search) (OR = 0.47; P < .01) and arteriolosclerosis (search) (OR = 0.53; P = .01) were lower, though odds for brain infarcts (OR = 1.74; P = .01) were higher, especially macroinfarcts (OR = 1.66; P = .03).
Notably, autopsied patients with all three classes also had less global Alzheimer's disease (search) pathology, primarily amyloid (search) and tangles (P < .01). The protective effects extended to other pathologies, with odds ratios of 0.46 for TDP-43 (P < .01) and 0.27 for hippocampal sclerosis (search) (P = .03).
Dose-Response Relationship Observed
The study revealed a clear dose-response relationship between the number of medication classes used and cognitive benefits. Patients who used two classes of medications experienced slower declines in global cognition (P < .01), especially in semantic and working memory. Autopsied patients who had used two classes had lower odds for atherosclerosis (search) (OR = 0.63; P < .01) and TDP-43 (OR = 0.71; P = .02) as well as less global Alzheimer's disease (search) pathology (P = .03) and fewer tangles (P = .03).
Even patients with one class of medication showed benefits, with slower semantic memory decline (P = .02). Autopsied patients who had used one class demonstrated fewer tangles (P = .02) and lower odds for TDP-43 (OR = 0.73; P = .02).
Clinical Implications and Future Research
"Our study suggests that early interventions with combination therapies targeting multiple vascular metabolic risk factors could potentially delay or prevent cognitive decline and dementia (search)," Biswas said. "However, these associations need to be studied further before making clinical recommendations."
The research builds on previous findings from Swedish national registers involving 8,065 incident dementia (search) cases, which showed that long-term users of multiple cardiovascular therapy classes had statistically significantly fewer dementia diagnoses (OR, 0.75–0.91) compared with non-users.
Future research will examine combinations of therapies that target metabolic risk factors and their associations with dementia (search) risk over time. "Additionally, as a next step, we would examine amongst each of the medication classes which subclass works better," Biswas noted. "For example, among antihypertensive medications (search) which subclass works better; and the same thing for lipid-lowering and antidiabetes medications (search)."